Advance in anti-cancer lead-compounds derived from natural products

WU Shanchao; SHENG Chunquan; ZHANG Wannian

doi:10.3969/j.issn.1006-0111.2014.05.005

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 32 Issue 5

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2014 > 32(5): 337-341,371

WU Shanchao, SHENG Chunquan, ZHANG Wannian. Advance in anti-cancer lead-compounds derived from natural products[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(5): 337-341,371. doi: 10.3969/j.issn.1006-0111.2014.05.005

Citation:

WU Shanchao, SHENG Chunquan, ZHANG Wannian. Advance in anti-cancer lead-compounds derived from natural products[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(5): 337-341,371. doi: 10.3969/j.issn.1006-0111.2014.05.005

Advance in anti-cancer lead-compounds derived from natural products

doi: 10.3969/j.issn.1006-0111.2014.05.005

School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2013-03-11
Rev Recd Date: 2013-06-25

Abstract

Cancer is a serious threat to human life and health. Therefore, there is an emergent need to develop novel anti-cancer agents with new structural type, new mechanism of action and higher efficacy. Natural products had played a key role in the discovery of anticancer agents. The anti-cancer activity, mechanism of action, structure and activity relationship of several lead-compounds which were derived from natural products were summarized in this review.
- natural products,
- anti-cancer lead-compounds,
- anti-cancer activity,
- mechanism of action,
- structure and activity relationship

References

[1]	Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years[J]. J Nat Prod,2007, 70 (3):461-477.
[2]	Kessler JH, Mullauer FB, de Roo GM, et al. Broad in vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types[J]. Cancer Lett,2007, 251 (1):132-145.
[3]	Zuco V, Supino R, Righetti SC, et al. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells[J]. Cancer Lett,2002, 175 (1):17-25.
[4]	Chintharlapalli S, Papineni S, Ramaiah SK, et al. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors[J]. Cancer Res,2007, 67 (6):2816-2823.
[5]	Mertens-Talcitt SU, Noratto GD, Li X, et al. Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo:role of Sp transcription factors and microRNA-27a:ZBTB10[J]. Mol Carcinog, 2012Mar7,doi: 10.1002/mc.21893.
[6]	Eichenmuller M, Hemmerlein B, Von Schweinits D, et al. Betulinic acid induces apoptosis and inhibits hedgehog signalling in rhabdomyosarcoma[J]. Br J Cancer, 2010, 103 (1):43-51.
[7]	Liu X, Jutooru I, Lei P, et al. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer[J]. Mol Cancer Ther, 2012, 11 (7):1421-1431.
[8]	Kama E,Szoka L, Palka JA, et al. Betulinic acid inhibits the expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in human endometrial adenocarcinoma cells[J]. Mol Cell Biochem, 2010, 340 (1-2):15-20.
[9]	Pandey MK, Sung B, Aggarwail BB, et al. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells[J]. Int J Cancer, 2010, 127 (2):282-292.
[10]	Liu Y, Luo W. Betulinic acid induces Bax/Bak-independent cytochrome C release in human nasopharyngeal carcinoma cells[J]. Mol Cells, 2012, 33 (5):517-524.
[11]	Yogeeswari P, Sriram D. Betulinic acid and its derivatives:a review on their biological properties[J]. Curr Med Chem, 2005, 12 (6):657-666.
[12]	Eiznhamer DA, Xu ZQ. Betulinic acid:a promising anticancer candidate[J]. I Drugs, 2004, 7 (4):359-373.
[13]	Chintharlli S, Papineni S, Lei P, et al. Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and-independent downregulation of specificity proteins (Sp) transcription factors[J]. BMC Cancer, 2011, 11:371.
[14]	Mukheijee R, Kumar V, Srivastava SK, et al. Betulinic acid derivatives as anticancer agents:structure activity relationship[J]. Anticancer Agents Med Chem, 2006, 6 (3):271-279.
[15]	Urban M, Vlkm M, Dzubak P, et al. Cytotoxic heterocyclic triterpenoids derived from betulin and betulinic acid[J]. Bioorg Med Chem, 2012, 20 (11):3666-3674.
[16]	Ahmad FB, Ghaffari Moghaddam M,Basri M, et al. Anticancer activity of 3-O-acylated betulinic acid derivatives obtained by enzymatic synthesis[J]. Biosci Biotechnol Biochem, 2010, 74 (5):1025-1029.
[17]	Kundu JK,Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol:mechanistic perspectives[J]. Cancer Lett, 2008, 269 (2):243-261.
[18]	Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes[J]. Science, 1997, 275 (5297):218-220.
[19]	Kundu JK, Surh YJ. Molecular basis of chemoprevention by resveratrol:NF-kappaB and AP-1 as potential targets[J]. Mutat Res, 2004, 555 (1-2):65-80.
[20]	Garg AK, Buchholz TA, Aggarwal BB. Chemosensitization and radiosensitization of tumors by plant polyphenols[J]. Antioxid Redox Signal, 2005, 7 (11-12):1630-1647.
[21]	Bhardwaj A, Sethi G, Vadhan-Raj S, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells[J]. Blood,2007, 109 (6):2293-2302.
[22]	Cai YJ, Wei QY, Fang JG, et al. The 3,4-dihydroxyl groups are important for trans-resveratrol analogs to exhibit enhanced antioxidant and apoptotic activities[J]. Anticancer Res, 2004, 24 (2B):999-1002.
[23]	Hung LM, Su MJ, Chu WK, et al. The protective effect of resveratrols on ischaemia-reperfusion injuries of rat hearts is correlated with antioxidant efficacy[J]. Br J Pharmacol, 2002, 135 (7):1627-1633.
[24]	Saiko P, Szakmary A, Jaeger W, et al. Resveratrol and its analogs:defense against cancer, coronary disease and neurodegenerative maladies or just a fad? [J]. Mutat Res, 2008, 658 (1-2):68-94.
[25]	Jiang GJ, Hu C. Evodiamine:a novel anti-cancer alkaloid from Evodia rutaecarpa[J]. Molecules, 2009, 14 (5):1852-1859.
[26]	Liao CH, Pan SL,Guh JH, et al.Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo[J]. Carcinogenesis, 2005, 26 (5):968-975.
[27]	Zhang C, Fan X, Xu X, et al. Evodiamine induces caspase-dependent apoptosis and S phase arrest in human colon lovo cells[J]. Anticancer Drugs, 2010, 21 (8):766-776.
[28]	Liao CH, Pan SL, Guh JH, et al. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo[J]. Carcinogenesis, 2005, 26 (5):968-975.
[29]	Lee TJ, Kim EJ, Kim S, et al. Caspase-dependent and caspase-independent apoptosis induced by evodiamine in human leukemic U937 cells[J]. Mol Cancer Ther, 2006, 5 (9):2398-2407.
[30]	Takada Y, Kobaysshi Y, Aggarwal BB. Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion[J]. J Biol Chem, 2005, 280 (17):17203-17212.
[31]	Yang ZG, Chen AQ, Liu B. Antiproliferation and apoptosis induced by evodiamine in human colorectal carcinoma cells (COLO-205)[J]. Chem Biodivers, 2009, 6 (6):924-933.
[32]	Huang H, Zhang Y, Liu X, et al. Acid sphingomyelinase contributes to evodiamine-induced apoptosis in human gastric cancer SGC-7901 cells[J]. DNA Cell Biol, 2011, 30 (6):407-412.
[33]	Rasul A, Yu B, Zhong L, et al. Cytotoxic effect of evodiamine in SGC-7901 human gastric adenocarcinoma cells via simultaneous induction of apoptosis and autophagy[J]. Oncol Rep, 2012, 27 (5):1481-1487.
[34]	Wei WT, Chen H, Wang ZH, et al. Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway[J]. Int J Biol Sci, 2012, 8 (1):1-14.
[35]	Dong G, Sheng C, Wang S, et al. Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents[J]. Med Chem, 2010,53 (21):7521-7531.
[36]	Sheng C, Miao Z, Zhang W. New strategies in the discovery of novel non-camptothecin topoisomerase I inhibitors[J]. Curr Med Chem, 2011, 18(28):4389-4409.
[37]	Anand P, Sundaram C, Jhurani S, et al. Curcumin and cancer:an "old-age" disease with an "age-old" solution[J]. Cancer Lett, 2008, 267 (1):133-164.
[38]	Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin":from kitchen to clinic[J]. Biochem Pharmacol, 2008, 75 (4):787-809.
[39]	Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases[J]. Int J Biochem Cell Biol, 2009, 41 (1):40-59.
[40]	Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin[J]. Adv Exp Med Biol, 2007, 595:127-148.
[41]	Qiu X, Liu Z, Shao WY, et al. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors[J]. Bioorg Med Chem, 2008, 16(17):8035-8041.
[42]	Safavy A, Raisch KP, Mantena S, et al. Design and development of water-soluble curcumin conjugates as potential anticancer agents[J]. J Med Chem, 2007, 50(24):6284-6288.
[43]	Raj L, Ide T, Chrkar AU, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS[J]. Nature, 2011, 475(7355):231-234.
[44]	Bazerra DP, Castro FO,Alves AP, et al. In vivo growth-inhibition of sarcoma 180 by piplartine and piperine, two alkaloid amides from Piper[J]. Braz J Med Biol Res, 2006, 39(6):801-807.
[45]	Bezerra DP, Militao GC, de Castro FO, et al.Piplartine induces inhibition of leukemia cell proliferation triggering both apoptosis and necrosis pathways[J]. Toxicol In Vitro, 2007, 21(1):1-8.
[46]	Golowine KV, Makhov PB, Teper E, et al. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells[J]. Prostate, 2013, 73(1):23.
[47]	Bezeera DP, de Castro FO, Alves AP, et al. In vitro and in vivo antitumor effect of 5-FU combined with piplartine and piperine[J]. J Appl Toxicol, 2008, 28(2):156-163.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(2997) PDF downloads(303) Cited by()

Proportional views

Advance in anti-cancer lead-compounds derived from natural products

School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2013-03-11

Rev Recd Date: 2013-06-25

Key words:

Abstract: Cancer is a serious threat to human life and health. Therefore, there is an emergent need to develop novel anti-cancer agents with new structural type, new mechanism of action and higher efficacy. Natural products had played a key role in the discovery of anticancer agents. The anti-cancer activity, mechanism of action, structure and activity relationship of several lead-compounds which were derived from natural products were summarized in this review.

HTML

Reference (47)

[1]	Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years[J]. J Nat Prod,2007, 70 (3):461-477.
[2]	Kessler JH, Mullauer FB, de Roo GM, et al. Broad in vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types[J]. Cancer Lett,2007, 251 (1):132-145.
[3]	Zuco V, Supino R, Righetti SC, et al. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells[J]. Cancer Lett,2002, 175 (1):17-25.
[4]	Chintharlapalli S, Papineni S, Ramaiah SK, et al. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors[J]. Cancer Res,2007, 67 (6):2816-2823.
[5]	Mertens-Talcitt SU, Noratto GD, Li X, et al. Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo:role of Sp transcription factors and microRNA-27a:ZBTB10[J]. Mol Carcinog, 2012Mar7,doi:10.1002/mc.21893.
[6]	Eichenmuller M, Hemmerlein B, Von Schweinits D, et al. Betulinic acid induces apoptosis and inhibits hedgehog signalling in rhabdomyosarcoma[J]. Br J Cancer, 2010, 103 (1):43-51.
[7]	Liu X, Jutooru I, Lei P, et al. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer[J]. Mol Cancer Ther, 2012, 11 (7):1421-1431.
[8]	Kama E,Szoka L, Palka JA, et al. Betulinic acid inhibits the expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in human endometrial adenocarcinoma cells[J]. Mol Cell Biochem, 2010, 340 (1-2):15-20.
[9]	Pandey MK, Sung B, Aggarwail BB, et al. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells[J]. Int J Cancer, 2010, 127 (2):282-292.
[10]	Liu Y, Luo W. Betulinic acid induces Bax/Bak-independent cytochrome C release in human nasopharyngeal carcinoma cells[J]. Mol Cells, 2012, 33 (5):517-524.
[11]	Yogeeswari P, Sriram D. Betulinic acid and its derivatives:a review on their biological properties[J]. Curr Med Chem, 2005, 12 (6):657-666.
[12]	Eiznhamer DA, Xu ZQ. Betulinic acid:a promising anticancer candidate[J]. I Drugs, 2004, 7 (4):359-373.
[13]	Chintharlli S, Papineni S, Lei P, et al. Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and-independent downregulation of specificity proteins (Sp) transcription factors[J]. BMC Cancer, 2011, 11:371.
[14]	Mukheijee R, Kumar V, Srivastava SK, et al. Betulinic acid derivatives as anticancer agents:structure activity relationship[J]. Anticancer Agents Med Chem, 2006, 6 (3):271-279.
[15]	Urban M, Vlkm M, Dzubak P, et al. Cytotoxic heterocyclic triterpenoids derived from betulin and betulinic acid[J]. Bioorg Med Chem, 2012, 20 (11):3666-3674.
[16]	Ahmad FB, Ghaffari Moghaddam M,Basri M, et al. Anticancer activity of 3-O-acylated betulinic acid derivatives obtained by enzymatic synthesis[J]. Biosci Biotechnol Biochem, 2010, 74 (5):1025-1029.
[17]	Kundu JK,Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol:mechanistic perspectives[J]. Cancer Lett, 2008, 269 (2):243-261.
[18]	Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes[J]. Science, 1997, 275 (5297):218-220.
[19]	Kundu JK, Surh YJ. Molecular basis of chemoprevention by resveratrol:NF-kappaB and AP-1 as potential targets[J]. Mutat Res, 2004, 555 (1-2):65-80.
[20]	Garg AK, Buchholz TA, Aggarwal BB. Chemosensitization and radiosensitization of tumors by plant polyphenols[J]. Antioxid Redox Signal, 2005, 7 (11-12):1630-1647.
[21]	Bhardwaj A, Sethi G, Vadhan-Raj S, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells[J]. Blood,2007, 109 (6):2293-2302.
[22]	Cai YJ, Wei QY, Fang JG, et al. The 3,4-dihydroxyl groups are important for trans-resveratrol analogs to exhibit enhanced antioxidant and apoptotic activities[J]. Anticancer Res, 2004, 24 (2B):999-1002.
[23]	Hung LM, Su MJ, Chu WK, et al. The protective effect of resveratrols on ischaemia-reperfusion injuries of rat hearts is correlated with antioxidant efficacy[J]. Br J Pharmacol, 2002, 135 (7):1627-1633.
[24]	Saiko P, Szakmary A, Jaeger W, et al. Resveratrol and its analogs:defense against cancer, coronary disease and neurodegenerative maladies or just a fad? [J]. Mutat Res, 2008, 658 (1-2):68-94.
[25]	Jiang GJ, Hu C. Evodiamine:a novel anti-cancer alkaloid from Evodia rutaecarpa[J]. Molecules, 2009, 14 (5):1852-1859.
[26]	Liao CH, Pan SL,Guh JH, et al.Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo[J]. Carcinogenesis, 2005, 26 (5):968-975.
[27]	Zhang C, Fan X, Xu X, et al. Evodiamine induces caspase-dependent apoptosis and S phase arrest in human colon lovo cells[J]. Anticancer Drugs, 2010, 21 (8):766-776.
[28]	Liao CH, Pan SL, Guh JH, et al. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo[J]. Carcinogenesis, 2005, 26 (5):968-975.
[29]	Lee TJ, Kim EJ, Kim S, et al. Caspase-dependent and caspase-independent apoptosis induced by evodiamine in human leukemic U937 cells[J]. Mol Cancer Ther, 2006, 5 (9):2398-2407.
[30]	Takada Y, Kobaysshi Y, Aggarwal BB. Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion[J]. J Biol Chem, 2005, 280 (17):17203-17212.
[31]	Yang ZG, Chen AQ, Liu B. Antiproliferation and apoptosis induced by evodiamine in human colorectal carcinoma cells (COLO-205)[J]. Chem Biodivers, 2009, 6 (6):924-933.
[32]	Huang H, Zhang Y, Liu X, et al. Acid sphingomyelinase contributes to evodiamine-induced apoptosis in human gastric cancer SGC-7901 cells[J]. DNA Cell Biol, 2011, 30 (6):407-412.
[33]	Rasul A, Yu B, Zhong L, et al. Cytotoxic effect of evodiamine in SGC-7901 human gastric adenocarcinoma cells via simultaneous induction of apoptosis and autophagy[J]. Oncol Rep, 2012, 27 (5):1481-1487.
[34]	Wei WT, Chen H, Wang ZH, et al. Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway[J]. Int J Biol Sci, 2012, 8 (1):1-14.
[35]	Dong G, Sheng C, Wang S, et al. Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents[J]. Med Chem, 2010,53 (21):7521-7531.
[36]	Sheng C, Miao Z, Zhang W. New strategies in the discovery of novel non-camptothecin topoisomerase I inhibitors[J]. Curr Med Chem, 2011, 18(28):4389-4409.
[37]	Anand P, Sundaram C, Jhurani S, et al. Curcumin and cancer:an "old-age" disease with an "age-old" solution[J]. Cancer Lett, 2008, 267 (1):133-164.
[38]	Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin":from kitchen to clinic[J]. Biochem Pharmacol, 2008, 75 (4):787-809.
[39]	Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases[J]. Int J Biochem Cell Biol, 2009, 41 (1):40-59.
[40]	Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin[J]. Adv Exp Med Biol, 2007, 595:127-148.
[41]	Qiu X, Liu Z, Shao WY, et al. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors[J]. Bioorg Med Chem, 2008, 16(17):8035-8041.
[42]	Safavy A, Raisch KP, Mantena S, et al. Design and development of water-soluble curcumin conjugates as potential anticancer agents[J]. J Med Chem, 2007, 50(24):6284-6288.
[43]	Raj L, Ide T, Chrkar AU, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS[J]. Nature, 2011, 475(7355):231-234.
[44]	Bazerra DP, Castro FO,Alves AP, et al. In vivo growth-inhibition of sarcoma 180 by piplartine and piperine, two alkaloid amides from Piper[J]. Braz J Med Biol Res, 2006, 39(6):801-807.
[45]	Bezerra DP, Militao GC, de Castro FO, et al.Piplartine induces inhibition of leukemia cell proliferation triggering both apoptosis and necrosis pathways[J]. Toxicol In Vitro, 2007, 21(1):1-8.
[46]	Golowine KV, Makhov PB, Teper E, et al. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells[J]. Prostate, 2013, 73(1):23.
[47]	Bezeera DP, de Castro FO, Alves AP, et al. In vitro and in vivo antitumor effect of 5-FU combined with piplartine and piperine[J]. J Appl Toxicol, 2008, 28(2):156-163.

Message Board

Advance in anti-cancer lead-compounds derived from natural products

doi: 10.3969/j.issn.1006-0111.2014.05.005

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views